Cytokinetics Announces Opening Of A Phase IIa “Evidence Of Effect” Clinical Trial Of CK-2017357 For Patients With Amyotrophic Lateral Sclerosis

Cytokinetics, Incorporated (NASDAQ: CYTK) announced that the company has opened a Phase IIa "Evidence of Effect" (EoE) clinical trial of CK-2017357 for patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. CK-2017357 is a fast skeletal muscle troponin activator and is the lead drug candidate that has emerged from the company's skeletal muscle contractility program...
This entry was posted in News from Other Sources. Bookmark the permalink. Both comments and trackbacks are currently closed.